There are currently 476 clinical trials in Rochester, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Rochester, University of Rochester Medical Center, James P. Wilmot Cancer Center at University of Rochester Medical Center and Rochester Clinical Research, Inc.. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318
Recruiting
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Wilmot Cancer Institute Radiation Oncology at Greece, Rochester, New York +2 locations
Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Register for Updates
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
NCT03233191
Recruiting
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Gender:
Female
Ages:
Between 45 years and 74 years
Trial Updated:
06/21/2023
Locations: University of Rochester, Rochester, New York
Conditions: Breast Screening
Register for Updates
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03267433
Recruiting
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone m... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/21/2023
Locations: University of Rochester, Rochester, New York
Conditions: CD20 Positive, Mantle Cell Lymphoma
Register for Updates
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139
Recruiting
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the exten... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Highland Hospital, Rochester, New York +1 locations
Conditions: Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Wilmot Cancer Institute Radiation Oncology at Greece, Rochester, New York +3 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention
NCT05764993
Recruiting
To examine the prevalence of humoral immunodeficiency in patients with Chronic Obstructive Pulmonary disease (COPD) by evaluating both immunoglobulin levels and vaccine responses. Patients with COPD and humoral dysfunction will be offered treatment with Subcutaneous Immune Globulin Replacement Therapy (SCIgR) in an attempt to decrease future AECOPD.
Gender:
All
Ages:
Between 18 years and 82 years
Trial Updated:
06/13/2023
Locations: Rochester Regional Health Ctr for Clinical Research - Alexander Park, Rochester, New York +2 locations
Conditions: COPD Exacerbation Acute
Register for Updates
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
NCT05433090
Recruiting
This is a pilot study to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies
Gender:
All
Ages:
60 years and above
Trial Updated:
06/07/2023
Locations: University of Rochester, Rochester, New York
Conditions: Hematologic Malignancies
Register for Updates
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
NCT05029960
Recruiting
The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Brain Tumor
Register for Updates
Academic-Community EPINET (AC-EPINET)
NCT04497857
Recruiting
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
Gender:
All
Ages:
Between 16 years and 35 years
Trial Updated:
05/16/2023
Locations: Strong Ties Young Adults Program- University of Rochester Medical Center, Rochester, New York
Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Register for Updates
Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)
NCT05197530
Recruiting
Lymphatic transport was previously examined by these investigators using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities. They established reliable and reproducible methodologies in RA patients. The purpose of this phase 2 pilot is to study RA disease progression and effectiveness as well as the mechanism of action of clinical interventions using established NIR-ICG methodologies in previous studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2023
Locations: University of Rochester, Rochester, New York
Conditions: Rheumatoid Arthritis
Register for Updates
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
NCT03739502
Recruiting
The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/01/2023
Locations: University of Rochester, Rochester, New York
Conditions: AML, NHL, Hodgkin Disease, All, Myelodysplastic Syndrome
Register for Updates
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634
Recruiting
The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo in prevention of oral mucositis (OM) in patients with HNSCC who are undergoing concurrent chemoradiotherapy (CCRT).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: James P. Wilmot Cancer Center, Rochester, New York
Conditions: Oral Mucositis, Head and Neck Squamous Cell Carcinoma
Register for Updates